ERYPED (erythromycin ethylsuccinate) by R-Pharm US is clinical pharmacology orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and nonfasting conditions. Approved for the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 8 more indications. First approved in 1970.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ERYPED (erythromycin ethylsuccinate) is an oral macrolide antibiotic indicated for bacterial and chlamydial infections, including newborn conjunctivitis, pneumonia of infancy, and urogenital infections. It works by inhibiting protein synthesis via 50S ribosomal subunit binding in susceptible organisms. The drug is readily absorbed orally and concentrates in the liver for biliary excretion.
Lifecycle stage indicates mature product with limited commercial expansion; team size likely stable to declining as patent LOE approaches.
CLINICAL PHARMACOLOGY Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and nonfasting conditions. Erythromycin diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the…
Worked on ERYPED at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ERYPED offers limited career growth opportunity; linked job count of zero reflects minimal active recruitment. Working on this product means managing legacy brand operations, ensuring compliance, and defending market share against competitors rather than driving innovation or commercial expansion.